Key result
Mitral repair one-year mortality drops ~73% since 1996, alongside significant survival improvements for TEER.
Why the study?
Mitral valve surgery is recommended for severe MR, but contemporary data on national surgical patterns and patient characteristics are lacking.
How have the incidence, patient characteristics, and one-year mortality of mitral valve surgery for mitral regurgitation evolved in Denmark from 1996 to 2022?
Observational (n=8,098)
Yes
How have the incidence, patient characteristics, and one-year mortality of mitral valve surgery for mitral regurgitation evolved in Denmark from 1996 to 2022?
Effect estimate: HR 0.27 (95% CI 0.15-0.49)
p-value: p=<0.001
Nationwide Danish data from 1996 to 2022 show increasing rates of mitral valve surgery, particularly repair and TEER, alongside significant improvements in one-year mortality for these procedures despite an aging patient population.
Mortality declines after mitral repair and TEER may reflect care evolution; extends observational trends but leaves causal mechanisms and practice change open.
BACKGROUND/AIMS: Mitral valve surgery (MVS) is recommended in severe mitral valve regurgitation (MR). Contemporary data on national surgical patterns and patient characteristics are lacking and are essential for the continuous epidemiologic monitoring of the disease. METHODS: Using Danish nationwide registries, patients undergoing MVS for MR between 1996 and 2022 were identified. Temporal trends in patient characteristics and annual incidence rates per 100,000 person years (PY) were computed. One-year cumulative mortality and mortality rates over calendar time were computed using the Kaplan-Meier estimator and multivariable adjusted Cox-analysis respectively. RESULTS: 8098 patients were included. Median age increased from 65.5 (1996-2001) to 69.4 years (2018-2022). Patients became less comorbid regarding ischemic heart disease and heart failure. The overall incidence rate of MVS increased from 4.09 to 8.66/100,000 PY (1996-2022), with significantly increasing incidences of mitral repair, biological replacement, and transcatheter-edge-to-edge repair (TEER), and significantly decreased incidence of mechanical replacement. The overall cumulative one-year mortalities were: TEER 18.9 %, biological replacement 15.5 %, mechanical replacement 10.2 %, mitral repair 4.8 %. Adjusted analysis showed a significant decrease in one-year mortality across time for mitral repair (HR 0.27 [95 % CI 0.15-0.49], p < 0.001) and TEER (HR 0.55 [95 % CI 0.31-0.97], p = 0.04). No significant mortality differences were observed for other interventions. CONCLUSIONS: From 1996 to 2022, more patients underwent mitral valve surgery driven by increasing incidence rates of mitral repair, biological replacement, and TEER. Patients got older but less comorbid regarding major cardiovascular comorbidities. Mortality significantly improved over time for patients undergoing mitral repair and TEER. Results could reflect earlier diagnosis and increased echocardiographic surveillance.
No takes yet. Share an insight, caveat, or question.
Schöps et al. (2025) conducted an observational in Mitral valve regurgitation (n=8,098). Mitral valve surgery vs. Calendar time was evaluated on One-year cumulative mortality (HR 0.27, 95% CI 0.15-0.49, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: